The new White House plan to import medicines from Canada is being billed as historic, but you better gas up if you think the proposal will save you from making a trip across the border to buy insulin.
Along with some other medicines known as biologics, which are typically administered by physicians, the diabetes treatment will not be part of the new proposal announced on Wednesday. Neither will many cancer medicines. And this is just one of several limitations to a plan that, in all fairness, holds some potential, but appears politically motivated more than anything else.
This is among the reasons I think the plan will have, at best, a modest impact. But before I delve into the nitty-gritty, let’s look at the politics.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect